文献速递认知障碍与痴呆神经肌肉病

40岁以下症状前C9orf72携带者的早期认知、结构与微结构改变

Early Cognitive, Structural, and Microstructural Changes in Presymptomatic C9orf72 Carriers Younger Than 40 Years.
PubMed 文献 · JAMA Neurol · 2018-01-01

PREV-DEMALS前瞻性多中心观察研究纳入80例C9orf72突变携带者一级亲属,比较C9+与C9-的神经心理和MRI指标,发现C9+在运用评分、多个皮层区及右侧丘脑体积、白质完整性上已有改变;40岁以下亚组仍见运用评分下降、4个皮层区及右侧丘脑萎缩和2条白质纤维束改变。

要点

  • 症状前C9orf72携带者已可检出认知、灰质体积和白质微结构改变。
  • 早期运用障碍可能反映左侧缘上回局灶萎缩,或为神经发育相关表型。
  • 白质改变可能预示未来额颞叶变性/肌萎缩侧索硬化表型,萎缩则更弥漫。

核心结论

  • 年轻C9orf72携带者已存在可检测的认知、结构和微结构改变。
  • 早期轻微运用障碍可能由左侧缘上回局灶萎缩 underpinning,或为神经发育相关且不进展的表型。
  • 白质改变反映未来额颞叶变性/肌萎缩侧索硬化的表型,而萎缩表现更弥漫。

研究设计与样本

  • PREV-DEMALS为前瞻性、多中心、观察性研究,纳入C9orf72突变携带者的一级亲属。
  • 所有参与者接受神经心理测试和磁共振成像,63人(79%)接受弥散张量磁共振成像。
  • 在感兴趣区内计算灰质体积和弥散张量成像指标,用线性混合效应模型比较C9+与C9-。

主要发现

  • 80例中C9+共41例(女性24例[59%],平均[SD]年龄39.8[11.1]岁),C9-共39例(女性24例[62%],平均[SD]年龄45.2[13.9]岁)。
  • 与C9-相比,C9+平均(SD)运用评分较低(163.4[6.1] vs 165.3[5.9];P=.01),不及物手势评分较低(34.9[1.6] vs 35.7[1.5];P=.004)。
  • C9+在8个皮层感兴趣区和右侧丘脑出现萎缩,并在8条白质纤维束出现白质改变。
  • 限制于40岁以下参与者时,C9+相比C9-运用评分和不及物手势评分较低,4个皮层感兴趣区和右侧丘脑萎缩,2条白质纤维束改变。

临床怎么用

  • 对于C9orf72突变携带者一级亲属,可在症状前阶段开展神经心理评估和MRI以捕捉早期生物标志物改变。
  • 运用功能和不及物手势评估可能有助于识别年轻C9orf72携带者的早期表型。
  • 灰质体积和弥散张量成像指标可作为监测治疗干预效果候选的临床前生物标志物。

局限性

  • 基线为横断面分析,不能确定认知、结构和微结构改变的纵向演变。
  • 仅63人(79%)完成弥散张量磁共振成像,白质指标样本量少于总样本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Presymptomatic carriers of chromosome 9 open reading frame 72 (C9orf72) mutation, the most frequent genetic cause of frontotemporal lobar degeneration and amyotrophic lateral sclerosis, represent the optimal target population for the development of disease-modifying drugs. Preclinical biomarkers are needed to monitor the effect of therapeutic interventions in this population. OBJECTIVES: To assess the occurrence of cognitive, structural, and microstructural changes in presymptomatic C9orf72 carriers. DESIGN, SETTING, AND PARTICIPANTS: The PREV-DEMALS study is a prospective, multicenter, observational study of first-degree relatives of individuals carrying the C9orf72 mutation. Eighty-four participants entered the study between October 2015 and April 2017; 80 (95%) were included in cross-sectional analyses of baseline data. All participants underwent neuropsychological testing and magnetic resonance imaging; 63 (79%) underwent diffusion tensor magnetic resonance imaging. Gray matter volumes and diffusion tensor imaging metrics were calculated within regions of interest. Anatomical and microstructural differences between individuals who carried the C9orf72 mutation (C9+) and those who did not carry the C9orf72 mutation (C9-) were assessed using linear mixed-effects models. Data were analyzed from October 2015 to April 2017. MAIN OUTCOMES AND MEASURES: Differences in neuropsychological scores, gray matter volume, and white matter integrity between C9+ and C9- individuals. RESULTS: Of the 80 included participants, there were 41 C9+ individuals (24 [59%] female; mean [SD] age, 39.8 [11.1] years) and 39 C9- individuals (24 [62%] female; mean [SD] age, 45.2 [13.9] years). Compared with C9- individuals, C9+ individuals had lower mean (SD) praxis scores (163.4 [6.1] vs 165.3 [5.9]; P = .01) and intransitive gesture scores (34.9 [1.6] vs 35.7 [1.5]; P = .004), atrophy in 8 cortical regions of interest and in the right thalamus, and white matter alterations in 8 tracts. When restricting the analyses to participants younger than 40 years, compared with C9- individuals, C9+ individuals had lower praxis scores and intransitive gesture scores, atrophy in 4 cortical regions of interest and in the right thalamus, and white matter alterations in 2 tracts. CONCLUSIONS AND RELEVANCE: Cognitive, structural, and microstructural alterations are detectable in young C9+ individuals. Early and subtle praxis alterations, underpinned by focal atrophy of the left supramarginal gyrus, may represent an early and nonevolving phenotype related to neurodevelopmental effects of C9orf72 mutation. White matter alterations reflect the future phenotype of frontotemporal lobar degeneration/amyotrophic lateral sclerosis, while atrophy appears more diffuse. Our results contribute to a better understanding of the preclinical phase of C9orf72 disease and of the respective contribution of magnetic resonance biomarkers. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02590276.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Bertrand A, Wen J, Rinaldi D, et al. Early Cognitive, Structural, and Microstructural Changes in Presymptomatic C9orf72 Carriers Younger Than 40 Years. JAMA Neurol. 2018. PMID: 29197216. doi:10.1001/jamaneurol.2017.4266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。